Sunday, September 02, 2012 10:28:04 AM
Yes, time needed for recruitment and implementation of a trial that might involve documentation of Median Overall Survival measured in years rather than months can breach the timing of the loan payback terms, calling on PPHM to come up with other funding sources. The new financing is structured to let PPHM get that second tranche only if the FDA Phase 3 trial approval has been achieved and the trial gets underway. Exercising of that path is something PPHM has indicated they would rather do with a partner, but if Pharma prospects are holding out, PPHM does have a path to keep things moving on their own. Serious Pharma partner finalization negotiations should be underway going into this Fall.
Best wishes and IMO.
KT
Cannabix Technologies Announces First Delivery of Marijuana Breath Test (MBT) to a Major Construction Client • BLOZF • Mar 19, 2026 12:45 PM
ECGI Building in Crypto's Top-Performing Sector as Tokenized Real-World Assets Surge Past $26 Billion • ECGI • Mar 19, 2026 8:30 AM
Advances in Domestic Heavy Rare Earth Minerals Production Essential for North American Defense Stockpiles • ALOY • Mar 18, 2026 9:00 AM
ECGI Advances $10M Mortgage Tokenization Pilot as SEC Interpretation Adds Clarity • ECGI • Mar 18, 2026 8:45 AM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
